Hester Biosciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
November 07, 2023 at 01:56 am EST
Share
Hester Biosciences Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 704.55 million compared to INR 731.53 million a year ago. Revenue was INR 748.13 million compared to INR 776.02 million a year ago. Net income was INR 40.86 million compared to INR 69.42 million a year ago. Basic earnings per share from continuing operations was INR 4.75 compared to INR 7.77 a year ago.
For the six months, sales was INR 1,583.08 million compared to INR 1,238.48 million a year ago. Revenue was INR 1,638.11 million compared to INR 1,314.2 million a year ago. Net income was INR 99.55 million compared to INR 109.1 million a year ago. Basic earnings per share from continuing operations was INR 12.64 compared to INR 11.95 a year ago.
Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.